Boustead-Led Activist Group Discloses 6.2% Stake and Launches Campaign Against Brera Holdings Board
SLMT is trading near its 52-week low of $3.81 (6.3% above the low).
Summary
A new activist group led by Boustead & Company and individuals Daniel McClory and Keith Moore has disclosed a 6.2% stake in Brera Holdings and launched a campaign against the board, alleging self-dealing and value destruction. The group is considering pushing for board changes or strategic alternatives.
Key Events · Ownership and Investor Activity · SLMT
-
New Activist Group Emerges
A group of investment banking professionals and entities, including Boustead & Company Ltd., Daniel McClory, and Keith Moore, disclosed a combined 6.2% stake (685,396 shares) and launched a public campaign against Brera Holdings' board and management.
-
Allegations of Self-Dealing and Entrenchment
The group alleges the board approved a $6M advisory agreement with a related entity, adopted a poison pill with a 9.99% trigger, and conducted a 21.4% dilutive registered direct offering to the CEO and a director that received a poison pill waiver, all of which entrenched incumbents and diluted other shareholders.
-
Reference to Shareholder Litigation
The filing notes a separate lawsuit filed by RBCH Ltd. on June 22, 2026, alleging breaches of fiduciary duty by certain directors, which the activist group is monitoring.
-
Group's Acquisition Costs and Sources
The group acquired its stake through a mix of warrant exercises, open-market purchases, and private transactions: BCL exercised warrants for 585,869 shares at a cost of $36.85M; Moore bought 20,850 shares for $1.37M; McClory bought 29,080 shares for $212,656; Pinehurst converted $2.7M debt for 50,033 shares; BREA paid $668,000 for 10,000 shares from co-founders.
Analysis · SLMT · Crypto Assets
A group of investment banking professionals and entities, led by Boustead & Company and individuals Daniel McClory and Keith Moore, has disclosed a combined 6.2% stake in Brera Holdings and launched a public activist campaign. The group alleges that the current board and management have destroyed shareholder value through self-dealing transactions, including a $6 million advisory agreement with a related entity, a poison pill that entrenches incumbents, and a highly dilutive registered direct offering to the CEO and a director that received a waiver from that poison pill. The filing also references a separate shareholder lawsuit alleging breaches of fiduciary duty. This escalates the ongoing boardroom battle that began in May 2026, adding a new, well-funded antagonist with deep capital markets expertise. The group states it may seek board changes, strategic alternatives, or other actions to unlock value.
At the time of this filing, SLMT was trading at $4.05 on NASDAQ in the Crypto Assets sector, with a market capitalization of approximately $43.3M. The 52-week trading range was $3.81 to $529.50. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.